

Rhode Island Department of Health Patricia A. Nolan, MD, MPH, Director

> Office of Health Statistics Turning numbers into knowledge www.healthri.org

January 2001 Vol. 3, No. 1

Edited by Jay S. Buechner, PhD

Invasive Disease Attributed to Streptococcus pneumoniae, 1998-1999

Tara A. Cooper, MPH, and Utpala Bandy, MD, MPH

Each year, Streptococcus pneumoniae infections cause an estimated 3,000 cases of meningitis, 50,000 cases of bacteremia, 500,000 cases of pneumonia, and 7 million cases of otitis media in the United States.1 Pneumococcal infection causes an estimated 40,000 deaths annually. Pneumococcal disease poses an even greater public health threat due to the proliferation of penicillin resistant strains. Many penicillin resistant strains of S. pneumoniae are also resistant to other antimicrobials.

The increasing prevalence of resistant organisms underscores the importance of primary prevention. The newly licensed pneumococcal conjugate vaccine for infants and toddlers has just been added to the state's universal vaccine distribution program. For adult Rhode Islanders, the pneumococcal polysaccharide vaccine can prevent a substantial number of pneumococcal infections; however only 55% of Rhode Islanders ages 65 years and older report that they have received pneumococcal vaccine.² (Table 1)

Methods. In 1996, information on antibiotic susceptibility for invasive Streptococcus pneumoniae became reportable in Rhode Island. In 1998, the Rhode Island Department of Health (HEALTH) embarked on a surveillance project to monitor

the incidence of invasive disease attributed to Streptococcus pneumoniae. For surveillance purposes, a case of invasive disease includes a person from whom S. pneumoniae was isolated from a normally sterile site (e.g., blood, pleural fluid, cerebrospinal fluid, peritoneal fluid, pericardial fluid, or synovial fluid and specimens collected during sterile procedures) in 1998 and 1999.

Cases were characterized according to their sensitivity to penicillin based on laboratory results. Intermediate susceptibility to penicillin was defined as a minimum inhibitory concentration (MIC) of 0.12-1.0 micrograms/mL; resistance to penicillin was defined as an MIC equal to or greater than 2.0 micrograms/mL.3 The term 'nonsusceptible" refers to both intermediate and resistant organisms. Patient medical records were reviewed for demographic and clinical information, including information on antibiotic susceptibility.

Results. In 1998, 210 reports were received and in 1999, 203 reports were received by HEALTH. Pneumococcal disease is primarily

a disease of the very young and the elderly. Case rates are high for children under five years of age, are low (less than 10.0/ 100,000) for ages 5-39, and then gradually increase to 70/100,000for those ages 70 and older. (Figure 1)

Slightly more cases during the two years were in males (50.8%). The rate of invasive disease was substantially higher among blacks compared to whites and Hispanics. (Table 2) The most common types of infection caused by Streptococcus pneumoniae included pneumonia (with bacteremia) in 67% of cases and primary bacteremia (21% of cases). Twelve percent of cases had other types of infection.

Forty-three cases died, for a mortality rate of 2.2/100,000. The age of fatal cases ranged from 30 to 95 years with a mean of 73.6 years and a median of 78.0 years. Higher rates have been reported in other studies; however, no long-term follow-up of cases

Table 1. Vaccination Rates for People Ages 65 and Older, Rhode Island, 1995-1999						
Type of Vaccine	1995	1997	1999			
Influenza	65.6%	67.7%	73.7%			
Pneumococcal	29.2%	43.0%	54.7%			
Source: See Reference 2						

Table 2. Incidence of Invasive Disease Attributed to
Streptococcus pneumoniae, by Gender, Race and Ethnicity,
Phodo Joland 1999 1999

Number of Cases	Percent of Cases	
210	50.8	
203	49.2	
413	100.0	
Number of Cases	R a t e 1	
330	19.2	
35	35.4	
21	16.1	
0		
1		
26		
413	20.9	
	210 203 413 Number of Cases 330 35 21 0 1 26	

population estimates from the U.S. Bureau of the Census.

Table 3. Antibiotic Susceptibility for Pneumococcal Isolates, Rhode Island, 1998-1999.

LEVEL OF RESISTANCE	1998 Number of Isolates	1998 Percent of Isolates	1999 Number of Isolates	1999 Percent of Isolates	
MIC Penicillin Resistant	12	5.7	15	7.4	
MIC Penicillin Intermediate	24	11.4	29	14.3	
Susceptible	173	82.3	149	73.4	
Unknown	1	0.6	10	4.9	
Total	210	100.0	203	100.0	

was conducted in this study as has been done in other studies.

Penicillin sensitivity information was received on 99.4% of cases in 1998 and 95.1% of cases in 1999. Of those cases with sensitivity data available, 17.1% of cases in 1998 were nonsusceptible and in 1999, 21.7% of cases were reported nonsusceptible. (Table 3) Susceptibility information on other commonly used antimicrobials was not as widely available.

Discussion. Two years of surveillance data for inva-




Figure 1. Incidence of Invasive Disease Attributed to Streptocococcus pneumoniae, by Age Group, Rhode Island, 1998-1999.

Originally published in the January 2001 issue of Medicine & Health / Rhode Island

artment of Health

Rhode Island Department of Health Office of Health Statistics 3 Capitol Hill Providence, Rhode Island 02908

Change service requested 401 222-2550

sive disease attributed to Streptococcus pneumoniae suggest

that this often preventable illness strikes the very young and the elderly. Blacks had higher incident rates of infection than whites or Hispanic persons. Clinically, the majority of cases presented with bacteremia and pneumonia. At the time of chart abstraction, 10.4% of cases had died.

The overall goal of this surveillance system is to determine statewide specific levels of resistance and make data available to assist clinicians in prescribing antimicrobials.

Preliminary surveillance data have provided baseline information on resistance rates in Rhode Island; a future challenge for HEALTH is to encourage complete antibiotic susceptibility testing including MICs for other broad-spectrum antibiotics. In addition, ongoing surveillance of age-specific morbidity will be useful to evaluate the

effectiveness of the adult and childhood vaccination programs.

In addition, HEALTH will continue to develop and integrate prevention and control strategies which include the development and marketing of educational materials for health care providers and the public about judicious use of antibiotics; the on-going promotion of pneumococcal polysaccharide vaccine; and promoting the integration of the newly licensed pneumococcal conjugate vaccine⁴ into the childhood vaccination schedule.

Tara A. Cooper, MPH is a Senior Public Health Epidemiologist, Division of Disease Prevention and Control.

Utpala Bandy, MD, MPH is the State Epidemiologist and Assistant Medical Director, Division of Disease Prevention and Control.

References

¹Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-8):1-24.

²Rhode Island Behavioral Risk Factor Surveillance System. Survey data; Rhode Island Department of Health, Office of Health Statistics; 1995,1997,1999.

³National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility test (M 100-S8), Vol. 18. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1998.

⁴Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-9):1-38.

PRSRT_STD U.S. Postage PAID Providence, R.I. 02904 Permit No. 1286